BioGenetics Seeks To Boost Pharma Business Via Kyung Nam Acquisition
Executive Summary
South Korean medical product manufacturer BioGenetics, which has recently diversified into the biopharma business and entered alliances for novel anticancer drugs, aims to further beef up its pharma activities through the acquisition of Kyung Nam Pharm, which will secure distribution networks at home and abroad.
You may also be interested in...
Conditions Converging For More M&A In Korean Pharma, Biotech
Merger and acquisition deals in South Korea’s pharma/biotech sector have remained relatively few compared to other countries, but several factors are now pointing to a possible increase in activity as pharma and biotech firms hunt for new technologies and growth.
Asia Deal Watch: Bharat Expands Its Vaccine Holdings By Buying GSK’s Chiron Behring
Bharat hopes to expand international reach of Chiron Behring’s rabies vaccine. WuXi and Biolingus partner on sublingual delivery.
From Science To Commercialization: How Genexine Is Making The Shift
Genexine CEO Neil Warma talks to Scrip in this audio interview about a wide range of topics, including key strategy changes, ambitions to become a leading global biopharma, as well as challenges he has faced since joining the Korean biotech.